No connection

Search Results

LUCD vs MGNX

LUCD
Lucid Diagnostics Inc.
BEARISH
Price
$1.28
Market Cap
$218.1M
Sector
Healthcare
AI Confidence
95%
MGNX
MacroGenics, Inc.
BEARISH
Price
$3.47
Market Cap
$220.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
LUCD
--
MGNX
--
Forward P/E
LUCD
-7.11
MGNX
-3.58
P/B Ratio
LUCD
-3.87
MGNX
3.95
P/S Ratio
LUCD
46.34
MGNX
1.48
EV/EBITDA
LUCD
-5.38
MGNX
-1.03

Profitability

Gross Margin
LUCD
-41.73%
MGNX
-22.53%
Operating Margin
LUCD
-931.58%
MGNX
-29.34%
Profit Margin
LUCD
0.0%
MGNX
-49.91%
ROE
LUCD
-710.6%
MGNX
-86.94%
ROA
LUCD
-87.2%
MGNX
-17.56%

Growth

Revenue Growth
LUCD
25.6%
MGNX
113.0%
Earnings Growth
LUCD
--
MGNX
--

Financial Health

Debt/Equity
LUCD
2.36
MGNX
0.66
Current Ratio
LUCD
1.31
MGNX
5.1
Quick Ratio
LUCD
1.27
MGNX
4.71

Dividends

Dividend Yield
LUCD
--
MGNX
--
Payout Ratio
LUCD
0.0%
MGNX
0.0%

AI Verdict

LUCD BEARISH

LUCD exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness in profitability, leverage, and operating efficiency. The company suffers from catastrophic operating margins (-931.58%) and negative shareholder equity (P/B of -3.87), suggesting a precarious balance sheet. While revenue growth remains positive at 25.6%, there is a massive disconnect between the fundamental decay and the 'Strong Buy' analyst consensus. The valuation is unjustifiable on a data-driven basis, with a Price/Sales ratio of 46.34 for a company consistently missing earnings estimates.

Strengths
Consistent year-over-year revenue growth of 25.60%
Current ratio of 1.31 provides a minimal short-term liquidity buffer
Strong analyst target price ($4.10) suggesting high speculative potential
Risks
Negative book value (P/B -3.87) indicating liabilities exceed assets
Extreme operating losses with an operating margin of -931.58%
Severe financial health deterioration (Piotroski 1/9)
MGNX BEARISH

MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.

Strengths
Exceptional YoY revenue growth of 113%
Strong short-term liquidity with a Current Ratio of 5.10
Manageable Debt/Equity ratio of 0.66
Risks
Critical fundamental health (Piotroski F-Score 0/9)
Negative gross margins (-22.53%) indicating an unsustainable cost structure
Severe earnings volatility and frequent misses (Average surprise -286.67%)

Compare Another Pair

LUCD vs MGNX: Head-to-Head Comparison

This page compares Lucid Diagnostics Inc. (LUCD) and MacroGenics, Inc. (MGNX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile